BOOM

Trending Searches

    SUPPORT
    BOOM

    Trending News

      • Fact Check 
        • Fast Check
        • Politics
        • Business
        • Entertainment
        • Social
        • Sports
        • World
      • Law
      • Explainers
      • News 
        • All News
      • Decode 
        • Impact
        • Scamcheck
        • Life
        • Voices
      • Media Buddhi 
        • Digital Buddhi
        • Senior Citizens
        • Videos
      • Web Stories
      • BOOM Research
      • BOOM Labs
      • Deepfake Tracker
      • Videos 
        • Facts Neeti
      • Home-icon
        Home
      • About Us-icon
        About Us
      • Authors-icon
        Authors
      • Team-icon
        Team
      • Careers-icon
        Careers
      • Internship-icon
        Internship
      • Contact Us-icon
        Contact Us
      • Methodology-icon
        Methodology
      • Correction Policy-icon
        Correction Policy
      • Non-Partnership Policy-icon
        Non-Partnership Policy
      • Cookie Policy-icon
        Cookie Policy
      • Grievance Redressal-icon
        Grievance Redressal
      • Republishing Guidelines-icon
        Republishing Guidelines
      • Fact Check-icon
        Fact Check
        Fast Check
        Politics
        Business
        Entertainment
        Social
        Sports
        World
      • Law-icon
        Law
      • Explainers-icon
        Explainers
      • News-icon
        News
        All News
      • Decode-icon
        Decode
        Impact
        Scamcheck
        Life
        Voices
      • Media Buddhi-icon
        Media Buddhi
        Digital Buddhi
        Senior Citizens
        Videos
      • Web Stories-icon
        Web Stories
      • BOOM Research-icon
        BOOM Research
      • BOOM Labs-icon
        BOOM Labs
      • Deepfake Tracker-icon
        Deepfake Tracker
      • Videos-icon
        Videos
        Facts Neeti
      Trending Tags
      TRENDING
      • #Operation Sindoor
      • #Pahalgam Terror Attack
      • #Narendra Modi
      • #Rahul Gandhi
      • #Waqf Amendment Bill
      • #Arvind Kejriwal
      • #Deepfake
      • #Artificial Intelligence
      • Home
      • Coronavirus
      • How Is Biological E's Corbevax...
      Coronavirus

      How Is Biological E's Corbevax Different From Other COVID Vaccines

      The scientists who designed the vaccine have waived off their patenting rights due to which the vaccine can be manufactured by other companies around the world

      By - Shachi Sutaria |
      Published -  13 Jan 2022 5:42 PM IST
    • Boomlive
      How Is Biological Es Corbevax Different From Other COVID Vaccines

      Corbevax, a protein sub-unit COVID-19 vaccine, manufactured by Hyderabad based Biological E and developed by scientists at the Baylor College of Medicine, Houston is the first patent free COVID-19 vaccine. This allows the technology to be replicated across the world for which Baylor college of medicine will receive a small free. This step will include a technology transfer and also reduce the costs of production of the vaccine.

      Furthermore, the vaccine uses an already established technology platform to release the protein sub-unit. The SARS-CoV-2 protein is released by a yeast which is how Hepatitis B vaccines are created as well. While Hep B vaccines use the yeast Saccharomyces cerevisiae as the host and medium for recombination, the COVID-19 vaccine uses another yeast called Pichia pastoris wherein the spike protein will replicate.

      The vaccine received emergency use authorisation in India on December 28, 2021 along with Covovax produced by Novovax and Serum Institute of India. However, it is unclear as to when the vaccine will be introduced into the vaccination program as India intends to continue providing Covishield and Covaxin as precautionary booster doses to the eligible population.

      The government of India has placed an order of 300 million doses of this vaccine. The scientists Peter Hotez and Maria Bottezi who developed the vaccine believe that this vaccine could act as perfect booster dose vaccine to curb the spread of the ongoing Omicron variant. Indian authorities are still vouching for homologous booster shots which means that health workers and those above 60 can only take Covishield or Covaxin as a precautionary dose depending on which vaccine was administered to them earlier. Although health officials have spoken about mixing vaccines, India has not yet decided to go ahead with the same.

      Also Read:Did You Accidently Drink Hand Sanitizer? Health Effects, What To Do

      How Is The Vaccine Unique?

      All the other available viruses are either using mRNA technology, inactivating the live virus, or using other viral vectors to create COVID-19 vaccines. Corbevax and Covovax use recombinant protein technology for creating the vaccines which is an established technology and platform to create vaccines against major diseases.

      In case of Corbevax, after the SARS-CoV-2 genome was made public in January and February 2020, scientists at Baylor College of Medicine chose to isolate the virus and separate the spike protein from the other proteins and replicating genome of the virus. The spike protein is the unit which assists SARS-CoV-2 and its many variants to bind faster to cells in the human body and makes it easier for the virus to enter the cells, proliferate, and replicate.

      Dr.Hotez and Dr. Bottezi and their team, then inserted the spike protein into the yeast thus allowing recombination. Recombinant proteins are those where specific proteins are allowed to replicate without the help of an original replicating RNA or DNA and allowed to express their role on their own. In this case, the spike protein was produced without any infectious components of the existing virus.

      Yeasts are used as the host as they grow rapidly and are easy to manipulate genetically. They also secrete the proteins outside their cell body thus allowing them to be used to create vaccines. The spike protein after replication was cleaned to remove all the remnants of the yeast and then later used with adjuvants like aluminium hydroxide gel and CpG 108 to enhance the expression of the vaccine. These adjuvants do not mix with the contents of the vaccine and act only as catalysts.

      The vaccine can then be administered. India's drug general and the Central Drugs Standard Control Organisation gave emergency use authorisation to the drug after its clinical trials showed positive results. The efficacy of the vaccine is estimated to be 90 per cent but the results have not yet been published in any peer-reviewed journal.

      Patent Free And Equitable

      The vaccine developers have decided to not apply any patents on the technology of the vaccine due to which it will be easier to replicate across the world. The makers want to ensure that the vaccine is made available to as many people and protect them from contracting severe disease.

      Along with being patent free, the medium yeast that the vaccine uses to grow the Spike protein is also cheap and easily available. This reduces the cost of making the vaccine. Recombinant protein technology has been a part of vaccine technology since the 1980s and is also used to make the Hepatitis B vaccine.

      As the cost of production is going to be lower, it is estimated that the vaccine could be available for ₹250 for one dose and about ₹400. Although India has purchased close to 300 million doses, there are no news on when the vaccine will be made available.

      According to the developers, Biological E has already manufactured close to 100 million doses and has the capability to manufacture the same in the upcoming year.

      Also Read:Explained: How Shelf Life Of COVID-19 Vaccines Are Determined


      Tags

      corbevaxCOVID-19
      Read Full Article
      Next Story
      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker. Please reload after ad blocker is disabled.
      X

      Subscribe to BOOM Newsletters

      👉 No spam, no paywall — but verified insights.

      Please enter a Email Address
      Subscribe for free!

      Stay Ahead of Misinformation!

      Please enter a Email Address
      Subscribe Now🛡️ 100% Privacy Protected | No Spam, Just Facts
      By subscribing, you agree with the Terms & conditions and Privacy Policy connected to the offer

      Thank you for subscribing!

      You’re now part of the BOOM community.

      Or, Subscribe to receive latest news via email
      Subscribed Successfully...
      Copy HTMLHTML is copied!
      There's no data to copy!